The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2019 Update on Salivary Gland Carcinoma: Anti-HER2 w/o or w/Chemo Docetaxel Is Highly Active for Salivary Duct, Levatinib As Palliative for Recurrent/Metastatic Adenoid Cystic Carcinoma

39 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login